There has been a long-standing debate about the optimal approach to statin use, including whether we should initiate therapy using a “fixed-dose”, high-potency statin, or whether we should “start low and go slow” by titrating the dose to a specific LDL-C target. The LODESTAR study was designed to determine if treating LDL-C to a target level produces similar cardiovascular outcomes when compared to a fixed-dose approach.
Guest Authors: Dawn Fuke, PharmD, BCPS and Catherine Behret, PharmD, BCACP
Music by Good Talk
The Importance of a Healthy Mind in Patients with an Unhealthy Heart
Addressing the Concerns and Needs of Transgender Persons
The Power of Pharmacist-to-Pharmacist Handoffs During Transitions of Care
Improving Access to Naloxone - Yes, Pharmacists (Nar)CAN!
Making the GRADE: It’s time to AGREE on better CPGs
If Your Heart’s Not into It, Do You Really Need to Take Your Meds?
Should We Hold Our Breath for Vitamin D in COPD?
Breaking Up is Hard to Do: Are E-Cigarettes the Solution Tobacco Cessation?
Need a VITALity Boost? Rethink Vitamin D and Fish Oil Supplements
D-PRESCRIBE Study: As Age Goes Up, The Medication Must Go Down!
Keeping Intensive Blood Pressure Goals in MIND: Does it Impact Cognitive Decline?
Is a Team-Based Approach in Primary Care Worth It?
Cardiovascular Risk with Elevated Triglycerides - Does Icosapent Ethyl REDUCE-IT?
Another Case of Newer Isn’t Always Better! Gabapentin vs. Pregabalin for Chronic Sciatica
Fall Risk and Benzos – Is Trazodone Really the Knight in Shining Armor?
Top Ten Things Every Clinician Should Know About the 2018 Cholesterol Guidelines
Another Attempt to ARRIVE at an Answer Using Aspirin for Primary Prevention
Does a “One-Size-Fits-All” Aspirin Dosing Approach Still Hold WEIGHT?
Aspirin for Primary Prevention of CV Events in Diabetes - Is the Evidence ASCENDing?
LDL Limbo: How Low is Too Low?
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive